Literature DB >> 30168119

Management of Small Renal Masses.

Avinash Chenam1, Clayton Lau2.   

Abstract

With the ubiquitous use of cross-sectional abdominal imaging in recent years, the incidence of small renal masses (SRMs) has increased, and the evaluation and management of SRMs have become important clinical issues. Diagnosing a mass in the early stages theoretically allows for high rates of cure but simultaneously risks overtreatment. In the past 20 years, surgical treatment of SRMs has transitioned from radical nephrectomy for all renal tumors, regardless of size, to elective partial nephrectomy whenever technically feasible. Additionally, newer approaches, including renal mass biopsy, active surveillance for select patients, and renal mass ablation, have been increasingly used. In this chapter, we review the current evidence-based papers covering aspects of the diagnosis and management of SRMs.

Entities:  

Keywords:  Active surveillance; Partial nephrectomy; Renal cell carcinoma; Small renal masses

Mesh:

Year:  2018        PMID: 30168119     DOI: 10.1007/978-3-319-93339-9_5

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


  2 in total

Review 1.  Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs.

Authors:  Jason Chibuk; Andi Flory; Kristina M Kruglyak; Nicole Leibman; Alexis Nahama; Nilesh Dharajiya; Dirk van den Boom; Taylor J Jensen; Jeffrey S Friedman; M Richard Shen; Francisco Clemente-Vicario; Ilya Chorny; John A Tynan; Katherine M Lytle; Lauren E Holtvoigt; Muhammed Murtaza; Luis A Diaz; Dana W Y Tsui; Daniel S Grosu
Journal:  Front Vet Sci       Date:  2021-03-23

2.  Global Analysis of Research Trends on Kidney Function After Nephron-Sparing Surgery: A Bibliometric and Visualised Study.

Authors:  Faris Abushamma; Abdulkarim Barqawi; Samah W Al-Jabi; Maha Akkawi; Mosab Maree; Sa'ed H Zyoud
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.